Lacerta Therapeutics Strengthens Its Position in the AAV Gene Therapy Space With New Leadership (AP News)

Lacerta Therapeutics Strengthens Its Position in the AAV Gene Therapy Space With New Leadership

UF startup and UF Innovate | Sid Martin Biotech alum Lacerta Therapeutics, a clinical-stage gene therapy company, announced new leadership. Dr. Edgar Rodriguez-Lebron, co-founder, will serve as president and chairman of the Board of Directors. Co-founders and scientific advisors, Drs. Ken Warrington and Coy Heldermon, will round out the additions to the board. The company anticipates rapid advancements in their gene therapy pipelines as the founders return to fuel their growth.

Dr. Edgar Rodriguez-Lebron, assistant professor at UF’s department of pharmacology and therapeutics, has held increasing roles at Lacerta as a scientific advisor, chief scientific officer, and now chairman of the board & president. Dr. Rodriguez-Lebron brings over two decades of research experience and entrepreneurial leadership to Lacerta. His research on gene-based strategies to treat Huntington’s disease, spinocerebellar ataxias and other neurodegenerative diseases has been funded by the NIH and multiple foundations. He has also secured tens of millions of dollars in non-dilutive funds to fuel Lacerta’s growth and commitment to finding a cure for rare CNS diseases. Dr. Rodriguez-Lebron will continue his affiliation with the University of Florida.

Learn more about Lacerta Therapeutics Strengthens Its Position in the AAV Gene Therapy Space With New Leadership.
X